Marksans Pharma Limited announces that UK MHRA has granted market authorisation to the company's wholly owned subsidiary Relonchem Limited for Fluoxetine 20mg/5ml Oral Solution.

Therapeutic use of the product is for treatment of depressive illness and other mental/mood disorders.

The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK.